AbbVie Inc. (ABBV) stock prices updated...
 

AbbVie Inc. stock price

AbbVie Inc. latest news:


  • 10/27/2017 10:33:34

    BRIEF-AbbVie, on conf call, says we need to see HCV market sort itself out

    * AbbVie CEO, on conf call, says we need to see HCV market sort itself out

  • 10/27/2017 08:55:25

    Why AbbVie Won Big in Q3, and Can Keep Winning


  • 10/27/2017 05:41:21

    AbbVie increases cash dividend by 11% ahead of earnings

    Ahead of its third-quarter earnings release on Friday, AbbVie Inc. said the board will increase the company's cash dividend by 11% to 71 cents a share from 64 cents. The dividend will be paid out Feb. 15, 2018 to shareholders of record as of Jan. 12, 2018. Since its inception in 2013, AbbVie has increased its dividend by more than 77%. Shares of AbbVie are up 43% in the year to date, while the S&P 500 index is up more than 14% and the Dow Jones Industrial Average is up more than 18%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/17/2017 19:49:17

    Where to Find Value in Healthcare Stocks

    0 45 Emerging Biotech Market Is It Time To Invest 6 10 Is Large Cap Biotech a Value Trap 160 Gilead Biogen and Bluebird 12 00 Generic Drug Companies Teva Valeant and AbbVie 15 50 Managed Healthcare Sector The Effects Of

  • 09/28/2017 14:46:25

    DexCom and Rite Aid tumble while Abbott and AbbVie rise

    DexCom and Rite Aid fall while Abbott Laboratories and AbbVie jump

  • 09/28/2017 10:45:56

    AbbVie and Amgen Reach Global Resolution of Humira


  • 09/18/2017 09:52:02

    BRIEF-AbbVie announces positive topline results from phase 3 trial evaluating Venclexta/Venclyxto tablets in combination with Rituxan

    * AbbVie announces positive topline results from phase 3 trial evaluating Venclexta™/Venclyxto™ (Venetoclax) tablets in combination with Rituxan® (Rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic Leukemia

  • 09/11/2017 09:17:10

    AbbVie says deaths in arthritis trial not linked to drug

    AbbVie Inc(ABBV) said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

  • 09/11/2017 09:16:49

    UPDATE 2-AbbVie says deaths in arthritis trial not linked to drug

    Sept 11 (Reuters) - AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.

  • 09/04/2017 00:24:38

    BRIEF-Inventiva and AbbVie extend agreement

    INVENTIVA SA: * INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.

  • More trends:

    Abercrombie & Fitch CompanyANF | Aberdeen Greater China FundGCH | Aberdeen Japan Equity FundJEQ | Aberdeen Singapore FundSGF | ABM Industries IncorporatedABM | Acadia Realty TrustAKR | Accenture plc.ACN | Acco Brands CorporationACCO | Accuride Corporation NewACW | Ace LimitedACE |